Skip to main content

Table 2 Most common grade 3 (Gr3) and grade 4 (Gr4) adverse events (AEs) in all patients

From: First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors

 

Dose Level 1

1 mg/kg

n = number of events in 4 patients/

12 doses

Dose Level 2

2 mg/kg

n = number of events in 7 patients/

34 doses

Dose Level 1.5

1.5 mg/kg

n = number of events in 6 patients/

23 doses

Cumulative Incidence

n = number of events in 17 patients/

69 doses (%)

Adverse Event

Gr 3

Gr 4

Gr 3

Gr 4

Gr 3

Gr 4

 

Anemia

  

2

   

2 (3%)

Febrile Neutropenia

  

2

1

1

 

4 (6%)

Sepsis

   

1

  

1 (0%)

Lymphocyte count decreased

1

 

4

2

 

1

8 (12%)

Neutrophil count decreased

2

4

2

10

1

7

26 (38%)

White blood cell decreased

2

 

7

2

1

4

16 (23%)

Hypertension

1

     

1 (0%)

  1. See Supplementary Table 2 for report of all AEs